Profile
Eliot R.
Charles worked as a Director at Novacea, Inc. He was a Partner at Apax Partners, Inc. in 2004-2005.
Charles served as the Chief Operating Officer at Principia Biopharma, Inc. and was a Venture Partner at New Leaf Venture Partners LLC.
He holds a doctorate from the Massachusetts Institute of Technology, an MBA from The University of Chicago, and undergraduate and graduate degrees from the University of Illinois.
Former positions of Eliot R. Charles
Companies | Position | End |
---|---|---|
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | Private Equity Investor | 19/05/2005 |
PRINCIPIA BIOPHARMA INC. | Chief Operating Officer | - |
New Leaf Venture Partners LLC
New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group. | Private Equity Investor | - |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Director/Board Member | - |
Training of Eliot R. Charles
The University of Chicago | Masters Business Admin |
Massachusetts Institute of Technology | Doctorate Degree |
University of Illinois | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
Apax Partners, Inc.
Apax Partners, Inc. Investment ManagersFinance Founded in 1976, Apax Partners, Inc. is a venture capital/private equity firm located in New York City. The firm is a subsidiary of London-based Apax Partners LLP | Finance |
Novacea, Inc.
Novacea, Inc. Pharmaceuticals: MajorHealth Technology Novacea, Inc. is a privately held biopharmaceutical company focused on licensing, developing and commercializing novel agents to revolutionize the treatment of cancer. Novacea’s in-licensed product portfolio features three clinical stage oncology therapeutics. The Company has two products which are anticipated to commence Phase 3 clinical trials in 2006, DN-101 and vinorelbine oral. Banoxantrone (AQ4N) is in Phase 1/2 clinical trials. It is located in South San Francisco, CA. | Health Technology |
New Leaf Venture Partners LLC
New Leaf Venture Partners LLC Investment ManagersFinance New Leaf Venture Partners LLC (New Leaf Ventures) is an independent Venture Capital firm founded by Jeani Delagardelle, Philippe Chambon, Vijay Lathi, Ron Hunt, James Niedel, and Kathy LaPorte. The firm is headquartered in New York. It spun out from Sprout Group. | Finance |
Principia Biopharma, Inc.
Principia Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Principia Biopharma, Inc. is a biopharmaceutical company, which engages in designing and developing oral therapies to patients with significant unmet medical needs in immunology and oncology. It operates through Tailored Covalency platform, which enables to develop small molecule inhibitors of enzymes and receptor ligands with potencies and selectivities that rival those of injectable biologics, yet maintain the convenience of a pill. Its product pipeline includes PRN1008, PRN2246, PRN1371, and immunoproteasome inhibitor. The company was founded by Jack Taunton and Richard A. Miller on October 6, 2008 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Eliot R. Charles